Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.81 |
| ▸ | BCR | P11274 | 11/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.79 |
| ▸ | EGFR | P00533 | 1/20 | 0.79 |
| ▸ | PRKCA | P17252 | 1/20 | 0.79 |
| ▸ | KIT | P10721 | 4/20 | 0.72 |
| ▸ | ABL2 | P42684 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798433 | 0.91 | ABL1 (0.83) | ABL1BCRPDGFRAPDGFRBEGFR | |
| SCHEMBL2944323 | 0.90 | ABL1 (0.66) | ABL1BCRPDGFRAPDGFRBEGFR | |
| SCHEMBL2004455 | 0.89 | PDGFRA (0.91) | ABL1BCRPDGFRAPDGFRBEGFR | |
| SCHEMBL9782 | 0.88 | PDGFRA (1.00) | ABL1BCRPDGFRAPDGFRBEGFR | |
| SCHEMBL29498750 | 0.88 | PDGFRA (1.00) | ABL1BCRPDGFRAPDGFRBEGFR | |
| SCHEMBL27604250 | 0.88 | ABL1 (0.78) | ABL1BCRPDGFRAPDGFRBEGFR | |
| SCHEMBL4801110 | 0.88 | ABL1 (0.84) | ABL1BCRPDGFRAPDGFRBEGFR | |
| Methane SCHEMBL5972158 | 0.87 | PDGFRA (0.98) | ABL1BCRPDGFRAPDGFRBEGFR | |
| SCHEMBL14487954 | 0.86 | ABL1 (0.79) | ABL1BCRPDGFRAPDGFRBEGFR | |
| SCHEMBL4802851 | 0.86 | ABL1 (0.83) | ABL1BCRPDGFRAPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1872850-A | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2006-12-06 | — | — | CN | claimed |
| CN-1525967-A | N-phenyl-2-pyrimidinamine derivatives | ��˹��ŵ�� | 2004-09-01 | — | — | CN | claimed |
| US-20040102453-A1 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2004-05-27 | — | — | US | claimed |
| EP-1322634-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2003-07-02 | — | — | EP | claimed |
| WO-2002022597-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | claimed |
| CN-100406452-C | N-phenyl-2-pyrimidinamine derivatives | NOVARTIS AG (CH) | 2008-07-30 | — | — | CN | disclosed |
| US-7329661-B2 | N-phenyl-3-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-7312216-B2 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20070265292-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | BUERGER HANS M | 2007-11-15 | — | — | US | disclosed |
| CN-1872850-A | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2006-12-06 | — | — | CN | disclosed |
| US-20060223818-A1 | N-phenyl-2-pyrimidine-amine derivatives | BUERGER HANS M | 2006-10-05 | — | — | US | disclosed |
| US-7081532-B2 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2006-07-25 | — | — | US | disclosed |
| CN-1525967-A | N-phenyl-2-pyrimidinamine derivatives | ��˹��ŵ�� | 2004-09-01 | — | — | CN | disclosed |
| US-20040102453-A1 | N-phenyl-2-pyrimidine-amine derivatives | NOVARTIS AG (CH) | 2004-05-27 | — | — | US | disclosed |
| EP-1322634-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | Novartis AG (CH) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002022597-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102453-A1 | N-phenyl-2-pyrimidine-amine derivatives | NUDT1, PNP, TYMP | ABL1 68/4885BCR 4165/4885PDGFRA 77/4885 |
| US-20060223818-A1 | N-phenyl-2-pyrimidine-amine derivatives | NUDT1, PNP, TYMP | ABL1 66/4885BCR 4195/4885PDGFRA 81/4885 |
| US-20070265292-A1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES | NUDT1, PNP, TYMP | ABL1 66/4885BCR 4195/4885PDGFRA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.